Suchergebnisse - "Subcutaneous (mesh)"

Pharmacokinetic Properties of a Once-Weekly Fixed-Ratio Combination of Insulin Icodec and Semaglutide Compared with Separate Administration of Each Component in Individuals with Type 2 Diabetes Mellitus

Autoren: Westergaard, Lisbet Alifrangis, Lene Buckley, Stephen T. et al.

Quelle: Clin Drug Investig

Schlagwörter: Male, Adult, Cross-Over Studies, Adolescent, Injections, Subcutaneous, Glucagon-Like Peptides, Middle Aged, Drug Administration Schedule, Young Adult, Drug Combinations, Insulin/administration, Adolescent [MeSH], Double-Blind Method [MeSH], Female [MeSH], Adult [MeSH], Drug Combinations [MeSH], Humans [MeSH], Hypoglycemic Agents/pharmacokinetics [MeSH], Diabetes Mellitus, Type 2/drug therapy [MeSH], Drug Administration Schedule [MeSH], Middle Aged [MeSH], Diabetes Mellitus, Type 2/blood [MeSH], Insulin/pharmacokinetics [MeSH], Glucagon-Like Peptides/pharmacology [MeSH], Injections, Subcutaneous [MeSH], Male [MeSH], Cross-Over Studies [MeSH], Young Adult [MeSH], Glucagon-Like Peptides/administration, Original Research Article, Glucagon-Like Peptides/pharmacokinetics [MeSH], Hypoglycemic Agents/administration, Diabetes Mellitus, Type 2, Double-Blind Method, Humans, Hypoglycemic Agents, Insulin, Female

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39488821
https://repository.publisso.de/resource/frl:6521895

Nasal and blood transcriptomic pathways underpinning the clinical response to grass pollen immunotherapy

Autoren: Altman, Matthew C Segnitz, R Max Larson, David et al.

Quelle: The Journal of Allergy and Clinical Immunology. 152(5)

Schlagwörter: 32 Biomedical and Clinical Sciences (for-2020), 3202 Clinical Sciences (for-2020), Genetics (rcdc), Clinical Trials and Supportive Activities (rcdc), Human Genome (rcdc), Lung (rcdc), Clinical Research (rcdc), Allergic Rhinitis (Hay Fever) (rcdc), 5.1 Pharmaceuticals (hrcs-rac), Inflammatory and immune system (hrcs-hc), Humans (mesh), Transcriptome (mesh), Leukocytes, Mononuclear (mesh), Pollen (mesh), Allergens (mesh), Desensitization, Immunologic (mesh), Sublingual Immunotherapy (mesh), Phleum (mesh), Injections, Subcutaneous (mesh), Rhinitis, Allergic (mesh), Allergen immunotherapy, sublingual immunotherapy, subcutaneous immunotherapy, RNA sequencing, allergic rhinitis, Leukocytes, Mononuclear (mesh), Humans (mesh), Phleum (mesh), Pollen (mesh), Allergens (mesh), Desensitization, Immunologic (mesh), Injections, Subcutaneous (mesh), Transcriptome (mesh), Sublingual Immunotherapy (mesh), Rhinitis, Allergic (mesh), Allergen immunotherapy, RNA sequencing, allergic rhinitis, subcutaneous immunotherapy, sublingual immunotherapy, Humans (mesh), Transcriptome (mesh), Leukocytes, Mononuclear (mesh), Pollen (mesh), Allergens (mesh), Desensitization, Immunologic (mesh), Sublingual Immunotherapy (mesh), Phleum (mesh), Injections, Subcutaneous (mesh), Rhinitis, Allergic (mesh), 1107 Immunology (for), Allergy (science-metrix), 3204 Immunology (for-2020)

Dateibeschreibung: application/pdf

Zugangs-URL: https://escholarship.org/uc/item/47n146vs
https://escholarship.org/content/qt47n146vs/qt47n146vs.pdf

Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH

Autoren: Loomba, Rohit Sanyal, Arun J Kowdley, Kris V et al.

Quelle: The New England Journal of Medicine. 389(11)

Schlagwörter: 32 Biomedical and Clinical Sciences (for-2020), 3202 Clinical Sciences (for-2020), Liver Disease (rcdc), Hepatitis (rcdc), Digestive Diseases (rcdc), Clinical Research (rcdc), Clinical Trials and Supportive Activities (rcdc), 6.1 Pharmaceuticals (hrcs-rac), Humans (mesh), Biopsy (mesh), Double-Blind Method (mesh), Fibroblast Growth Factors (mesh), Fibrosis (mesh), Gastrointestinal Agents (mesh), Injections, Subcutaneous (mesh), Non-alcoholic Fatty Liver Disease (mesh), Treatment Outcome (mesh), Humans (mesh), Fibrosis (mesh), Fibroblast Growth Factors (mesh), Gastrointestinal Agents (mesh), Biopsy (mesh), Treatment Outcome (mesh), Injections, Subcutaneous (mesh), Double-Blind Method (mesh), Non-alcoholic Fatty Liver Disease (mesh), Humans (mesh), Biopsy (mesh), Double-Blind Method (mesh), Fibroblast Growth Factors (mesh), Fibrosis (mesh), Gastrointestinal Agents (mesh), Injections, Subcutaneous (mesh), Non-alcoholic Fatty Liver Disease (mesh), Treatment Outcome (mesh), 11 Medical and Health Sciences (for), General & Internal Medicine (science-metrix), 32 Biomedical and clinical sciences (for-2020), 42 Health sciences (for-2020)

Dateibeschreibung: application/pdf

Zugangs-URL: https://escholarship.org/uc/item/6t8299xv
https://escholarship.org/content/qt6t8299xv/qt6t8299xv.pdf

A Long-Term Safety and Tolerability Study of TV-46000 for Subcutaneous Use in Patients with Schizophrenia: A Phase 3, Randomized, Double-Blinded Clinical Trial

Autoren: Kane, John M. Eshet, Roy Harary, Eran et al.

Quelle: CNS Drugs

Schlagwörter: Male, Adult, Injections, Subcutaneous, Middle Aged, Risperidone, Young Adult, Treatment Outcome, Double-Blind Method, Delayed-Action Preparations, Double-Blind Method [MeSH], Female [MeSH], Antipsychotic Agents/administration, Antipsychotic Agents/adverse effects [MeSH], Adult [MeSH], Humans [MeSH], Risperidone/adverse effects [MeSH], Treatment Outcome [MeSH], Middle Aged [MeSH], Schizophrenia/drug therapy [MeSH], Injections, Subcutaneous [MeSH], Male [MeSH], Young Adult [MeSH], Delayed-Action Preparations [MeSH], Original Research Article, Risperidone/administration, Schizophrenia, Humans, Female, Antipsychotic Agents

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38954317
https://repository.publisso.de/resource/frl:6520471

Quality of counseling for self-administering injectable contraception: field evidence from mystery client interactions in Lagos, Nigeria

Autoren: Sneha Challa Calvin Chiu Ayobambo Jegede et al.

Quelle: BMC Women's Health, vol 25, iss Suppl 1

Schlagwörter: Prevention (rcdc), Subcutaneous (mesh), 1117 Public Health and Health Services (for), Mystery clients, Nigeria, Medroxyprogesterone Acetate (mesh), 1114 Paediatrics and Reproductive Medicine (for), Injections, Contraception (mesh), Clinical Research (rcdc), Contraceptive Agents, Contraception/Reproduction (rcdc), Middle Aged (mesh), 3215 Reproductive medicine (for-2020), Family planning, 42 Health Sciences (for-2020), Counseling (mesh), Humans (mesh), Self Administration (mesh), Young Adult (mesh), 3 Good Health and Well Being (sdg), Nigeria (mesh), Generic health relevance (hrcs-hc), Quality of care, Self-injection, 4203 Health Services and Systems (for-2020), 4204 Midwifery (for-2020), 1110 Nursing (for), 4206 Public health (for-2020), Female (mesh), Adult (mesh), Self-care, Behavioral and Social Science (rcdc), Obstetrics & Reproductive Medicine (science-metrix)

Zugangs-URL: https://escholarship.org/uc/item/2n37p4jz

Comparative Efficacy of Subcutaneous and Intravenous Infliximab and Vedolizumab for Maintenance Treatment of TNF-naive Adult Patients with Inflammatory Bowel Disease: A Systematic Literature Review and Network Meta-analysis: A Systematic Literature Review and Network Meta-analysis

Autoren: L. Peyrin-Biroulet P. Bossuyt D. Bettenworth et al.

Weitere Verfasser: L. Peyrin-Biroulet P. Bossuyt D. Bettenworth et al.

Quelle: Dig Dis Sci

Schlagwörter: Crohn's disease, Monoclonal antibody, Adult, Biologic, Injections, Subcutaneous, Remission Induction, Network Meta-Analysis, Antibodies, Monoclonal, Humanized, General medicine, internal medicine and other clinical medicine, Infliximab, Crohn Disease/drug therapy [MeSH], Maintenance Chemotherapy/methods [MeSH], Adult [MeSH], Humans [MeSH], Systematic review, Treatment Outcome [MeSH], Infliximab/administration, Antibodies, Monoclonal, Humanized/administration, Administration, Intravenous [MeSH], Injections, Subcutaneous [MeSH], Original Article, Randomized Controlled Trials as Topic [MeSH], Colitis, Ulcerative/drug therapy [MeSH], Network meta-analysis, Infliximab/therapeutic use [MeSH], Gastrointestinal Agents/therapeutic use [MeSH], Antibodies, Monoclonal, Humanized/therapeutic use [MeSH], Remission Induction [MeSH], Ulcerative colitis, Gastrointestinal Agents/administration, Maintenance Chemotherapy, Treatment Outcome, Gastrointestinal Agents, Crohn Disease, Humans, Colitis, Ulcerative, Administration, Intravenous, Randomized Controlled Trials as Topic

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38499736
https://pure.amsterdamumc.nl/en/publications/e5b8cb4f-aa08-431f-a484-2b90d6bc93de
https://doi.org/10.1007/s10620-023-08252-1
http://hdl.handle.net/10138/575877
https://repository.publisso.de/resource/frl:6501238

Teclistamab in Relapsed or Refractory Multiple Myeloma

Autoren: Moreau, Philippe Garfall, Alfred L van de Donk, Niels WCJ et al.

Quelle: The New England Journal of Medicine. 387(6)

Schlagwörter: 32 Biomedical and Clinical Sciences (for-2020), 3201 Cardiovascular Medicine and Haematology (for-2020), 3211 Oncology and Carcinogenesis (for-2020), Rare Diseases (rcdc), Immunotherapy (rcdc), Hematology (rcdc), 6.1 Pharmaceuticals (hrcs-rac), 6.2 Cellular and gene therapies (hrcs-rac), Cancer (hrcs-hc), Antibodies, Bispecific (mesh), Antibodies, Monoclonal, Humanized (mesh), Antineoplastic Agents (mesh), Antineoplastic Agents, Immunological (mesh), Antineoplastic Combined Chemotherapy Protocols (mesh), B-Cell Maturation Antigen (mesh), CD3 Complex (mesh), Humans (mesh), Injections, Subcutaneous (mesh), Multiple Myeloma (mesh), Neoplasm Recurrence, Local (mesh), Recurrence (mesh), T-Lymphocytes (mesh), T-Lymphocytes (mesh), Humans (mesh), Multiple Myeloma (mesh), Neoplasm Recurrence, Local (mesh), Recurrence (mesh), Antineoplastic Agents (mesh), Antineoplastic Combined Chemotherapy Protocols (mesh), Antibodies, Bispecific (mesh), Injections, Subcutaneous (mesh), B-Cell Maturation Antigen (mesh), Antibodies, Monoclonal, Humanized (mesh), Antineoplastic Agents, Immunological (mesh), CD3 Complex (mesh), Antibodies, Bispecific (mesh), Antibodies, Monoclonal, Humanized (mesh), Antineoplastic Agents (mesh), Antineoplastic Agents, Immunological (mesh), Antineoplastic Combined Chemotherapy Protocols (mesh), B-Cell Maturation Antigen (mesh), CD3 Complex (mesh), Humans (mesh), Injections, Subcutaneous (mesh), Multiple Myeloma (mesh), Neoplasm Recurrence, Local (mesh), Recurrence (mesh), T-Lymphocytes (mesh), 11 Medical and Health Sciences (for), General & Internal Medicine (science-metrix), 32 Biomedical and clinical sciences (for-2020), 42 Health sciences (for-2020)

Dateibeschreibung: application/pdf

Zugangs-URL: https://escholarship.org/uc/item/0nq4x6t9
https://escholarship.org/content/qt0nq4x6t9/qt0nq4x6t9.pdf

Tralokinumab Efficacy Over 1 Year in Adults with Moderate-to-Severe Atopic Dermatitis: Pooled Data from Two Phase III Trials

Autoren: Simpson, Eric Pink, Andrew Blauvelt, Andrew et al.

Weitere Verfasser: Simpson, Eric Pink, Andrew Blauvelt, Andrew et al.

Quelle: Am J Clin Dermatol

Schlagwörter: Adult, [SDV]Life Sciences [q-bio], Injections, Subcutaneous, Double-Blind Method [MeSH], Adult [MeSH], Humans [MeSH], Dermatitis, Atopic/diagnosis [MeSH], Severity of Illness Index [MeSH], Treatment Outcome [MeSH], Glucocorticoids/therapeutic use [MeSH], Clinical Trials, Phase III as Topic [MeSH], Injections, Subcutaneous [MeSH], Randomized Controlled Trials as Topic [MeSH], Immunoglobulin A [MeSH], Antibodies, Monoclonal, Humanized [MeSH], Medical and Health Sciences, Dermatologic Agents/therapeutic use [MeSH], Original Research Article, Dermatitis, Atopic/drug therapy [MeSH], Antibodies, Monoclonal, Humanized, Severity of Illness Index, 3. Good health, Dermatitis, Atopic, Immunoglobulin A, dermatology, [SDV] Life Sciences [q-bio], Treatment Outcome, Double-Blind Method, Clinical Trials, Phase III as Topic, Humans, Dermatologic Agents, Glucocorticoids, Atopic dermatitis, Randomized Controlled Trials as Topic

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/37682422
https://hdl.handle.net/10807/249921
https://doi.org/10.1007/s40257-023-00806-3
https://repository.publisso.de/resource/frl:6484523
https://hal.inrae.fr/hal-04247615v1/document
https://hal.inrae.fr/hal-04247615v1
https://doi.org/10.1007/s40257-023-00806-3
https://epub.ub.uni-muenchen.de/116318/

Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial

Autoren: Loomba, Rohit Morgan, Erin Watts, Lynnetta et al.

Quelle: The Lancet Gastroenterology & Hepatology. 5(9)

Schlagwörter: 32 Biomedical and Clinical Sciences (for-2020), 3202 Clinical Sciences (for-2020), Clinical Research (rcdc), Digestive Diseases (rcdc), Liver Disease (rcdc), Clinical Trials and Supportive Activities (rcdc), Chronic Liver Disease and Cirrhosis (rcdc), 6.1 Pharmaceuticals (hrcs-rac), 3 Good Health and Well Being (sdg), Aged (mesh), Body Mass Index (mesh), Canada (mesh), Case-Control Studies (mesh), Diabetes Mellitus, Type 2 (mesh), Diacylglycerol O-Acyltransferase (mesh), Double-Blind Method (mesh), Drug Tolerance (mesh), Female (mesh), Humans (mesh), Hungary (mesh), Injections, Subcutaneous (mesh), Intra-Abdominal Fat (mesh), Magnetic Resonance Imaging (mesh), Male (mesh), Middle Aged (mesh), Non-alcoholic Fatty Liver Disease (mesh), Oligonucleotides, Antisense (mesh), Placebos (mesh), Poland (mesh), Safety (mesh), Treatment Outcome (mesh), Humans (mesh), Diabetes Mellitus, Type 2 (mesh), Oligonucleotides, Antisense (mesh), Placebos (mesh), Magnetic Resonance Imaging (mesh), Body Mass Index (mesh), Treatment Outcome (mesh), Injections, Subcutaneous (mesh), Case-Control Studies (mesh), Double-Blind Method (mesh), Safety (mesh), Drug Tolerance (mesh), Aged (mesh), Middle Aged (mesh), Canada (mesh), Hungary (mesh), Poland (mesh), Female (mesh), Male (mesh), Intra-Abdominal Fat (mesh), Diacylglycerol O-Acyltransferase (mesh), Non-alcoholic Fatty Liver Disease (mesh), Aged (mesh), Body Mass Index (mesh), Canada (mesh), Case-Control Studies (mesh), Diabetes Mellitus, Type 2 (mesh), Diacylglycerol O-Acyltransferase (mesh), Double-Blind Method (mesh), Drug Tolerance (mesh), Female (mesh), Humans (mesh), Hungary (mesh), Injections, Subcutaneous (mesh), Intra-Abdominal Fat (mesh), Magnetic Resonance Imaging (mesh), Male (mesh), Middle Aged (mesh), Non-alcoholic Fatty Liver Disease (mesh), Oligonucleotides, Antisense (mesh), Placebos (mesh), Poland (mesh), Safety (mesh), Treatment Outcome (mesh), 3202 Clinical sciences (for-2020)

Zugangs-URL: https://escholarship.org/uc/item/3q1381st

Safety, Tolerability, and Pharmacokinetics of the Broadly Neutralizing Human Immunodeficiency Virus (HIV)-1 Monoclonal Antibody VRC01 in HIV-Exposed Newborn Infants

Autoren: Cunningham, Coleen K McFarland, Elizabeth J Morrison, R Leavitt et al.

Quelle: The Journal of Infectious Diseases. 222(4)

Schlagwörter: 3207 Medical Microbiology (for-2020), 32 Biomedical and Clinical Sciences (for-2020), 3204 Immunology (for-2020), Biotechnology (rcdc), Vaccine Related (AIDS) (rcdc), Infectious Diseases (rcdc), Pediatric (rcdc), Vaccine Related (rcdc), Sexually Transmitted Infections (rcdc), Prevention (rcdc), Immunization (rcdc), Perinatal Period - Conditions Originating in Perinatal Period (rcdc), HIV/AIDS (rcdc), Pediatric AIDS (rcdc), Breastfeeding, Lactation and Breast Milk (rcdc), Clinical Research (rcdc), 6.1 Pharmaceuticals (hrcs-rac), Reproductive health and childbirth (hrcs-hc), Infection (hrcs-hc), 3 Good Health and Well Being (sdg), Africa (mesh), Antibodies, Monoclonal (mesh), Broadly Neutralizing Antibodies (mesh), Female (mesh), HIV Antibodies (mesh), HIV Infections (mesh), HIV-1 (mesh), Humans (mesh), Infant, Newborn (mesh), Infectious Disease Transmission, Vertical (mesh), Injections, Subcutaneous (mesh), Linear Models (mesh), Male (mesh), United States (mesh), broadly neutralizing antibodies, HIV-1, mother-to-child transmission of HIV, neonates, VRC01, IMPAACT P1112 team, Humans (mesh), HIV-1 (mesh), HIV Infections (mesh), Antibodies, Monoclonal (mesh), HIV Antibodies (mesh), Injections, Subcutaneous (mesh), Linear Models (mesh), Infant, Newborn (mesh), Africa (mesh), United States (mesh), Female (mesh), Male (mesh), Infectious Disease Transmission, Vertical (mesh), Broadly Neutralizing Antibodies (mesh), HIV-1, VRC01, broadly neutralizing antibodies, mother-to-child transmission of HIV, neonates, Africa (mesh), Antibodies, Monoclonal (mesh), Broadly Neutralizing Antibodies (mesh), Female (mesh), HIV Antibodies (mesh), HIV Infections (mesh), HIV-1 (mesh), Humans (mesh), Infant, Newborn (mesh), Infectious Disease Transmission, Vertical (mesh), Injections, Subcutaneous (mesh), Linear Models (mesh), Male (mesh), United States (mesh), 06 Biological Sciences (for), 11 Medical and Health Sciences (for), Microbiology (science-metrix), 31 Biological sciences (for-2020), 32 Biomedical and clinical sciences (for-2020), 42 Health sciences (for-2020)

Dateibeschreibung: application/pdf

Zugangs-URL: https://escholarship.org/uc/item/8k24t7np
https://escholarship.org/content/qt8k24t7np/qt8k24t7np.pdf

Subcutaneous infliximab in Crohn’s disease patients with previous immunogenic failure of intravenous infliximab

Autoren: Husman, Julia Černá, Karin Matthes, Katja et al.

Quelle: Int J Colorectal Dis

Schlagwörter: Male, Adult, Research, Injections, Subcutaneous, Middle Aged, Crohn Disease/drug therapy [MeSH], Subcutaneous infliximab, Female [MeSH], Adult [MeSH], Humans [MeSH], Immunogenic failure, Infliximab/administration, Retrospective Studies [MeSH], CT-P13, Middle Aged [MeSH], Administration, Intravenous [MeSH], Injections, Subcutaneous [MeSH], Treatment Failure [MeSH], Infliximab/therapeutic use [MeSH], Male [MeSH], Feces/chemistry [MeSH], Young Adult [MeSH], Crohn Disease/immunology [MeSH], Infliximab/immunology [MeSH], Leukocyte L1 Antigen Complex/analysis [MeSH], Refractory Crohn's disease, Infliximab, Feces, Young Adult, Crohn Disease, Humans, Female, Administration, Intravenous, Treatment Failure, Leukocyte L1 Antigen Complex, Retrospective Studies

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39317813
https://repository.publisso.de/resource/frl:6523700

Pharmacokinetic and Pharmacodynamic Characteristics of Insulin Icodec After Subcutaneous Administration in the Thigh, Abdomen or Upper Arm in Individuals with Type 2 Diabetes Mellitus

Autoren: Plum-Mörschel, Leona Andersen, Lizette Ravn Hansen, Solvejg et al.

Quelle: Clin Drug Investig

Schlagwörter: Arm [MeSH], Injections, Subcutaneous [MeSH], Medical and Health Sciences, Glucose/therapeutic use [MeSH], Hypoglycemic Agents [MeSH], Humans [MeSH], Diabetes Mellitus, Type 2/drug therapy [MeSH], Original Research Article, Thigh [MeSH], Abdomen [MeSH], 03 medical and health sciences, Glucose, 0302 clinical medicine, Diabetes Mellitus, Type 2, Thigh, Injections, Subcutaneous, Abdomen, Arm, Humans, Hypoglycemic Agents, 3. Good health

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/36631720
https://repository.publisso.de/resource/frl:6486174

heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer

Autoren: Kuemmel S. Harper-Wynne C. Park Y. H. et al.

Quelle: BMC Cancer
BMC Cancer, Vol 24, Iss 1, Pp 1-14 (2024)

Schlagwörter: Breast cancer, Estrogen receptor-positive, Giredestrant, HER2-positive, Pertuzumab, Trastuzumab, Adult, 0301 basic medicine, Receptor, ErbB-2, Injections, Subcutaneous, Breast Neoplasms, Antibodies, Monoclonal, Humanized, Study Protocol, 03 medical and health sciences, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, Humans, Neoplasm Metastasis, RC254-282, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Middle Aged, 3. Good health, Receptors, Estrogen, Receptor, ErbB-2/metabolism [MeSH], Trastuzumab/administration, Antibodies, Monoclonal, Humanized/administration, Trastuzumab/therapeutic use [MeSH], Breast Neoplasms/pathology [MeSH], Female [MeSH], Receptors, Estrogen/metabolism [MeSH], Adult [MeSH], Humans [MeSH], Neoplasm Metastasis [MeSH], Breast Neoplasms/genetics [MeSH], Breast Neoplasms/drug therapy [MeSH], Breast Neoplasms/metabolism [MeSH], Middle Aged [MeSH], Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH], Antineoplastic Combined Chemotherapy Protocols/adverse effects [MeSH], Injections, Subcutaneous [MeSH], Antibodies, Monoclonal, Humanized/therapeutic use [MeSH], Antibodies, Monoclonal, Humanized/adverse effects [MeSH], Female

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38789924
https://doaj.org/article/e5f45a7c5b7e4bb7bb99b0bb30af3b2c
https://hdl.handle.net/11588/963524
https://repository.publisso.de/resource/frl:6504043

Adherence to Subcutaneous Interferon Beta-1a in Multiple Sclerosis Patients Receiving Periodic Feedback on Drug Use by Discussion of Readouts of Their Rebismart® Injector: Results of the Prospective Cohort Study REBIFLECT

Autoren: Rieckmann, Peter Ziemssen, Tjalf Penner, Iris-Katarina et al.

Quelle: Adv Ther

Schlagwörter: Multiple Sclerosis, Substance-Related Disorders, Injections, Subcutaneous, 3. Good health, Feedback, 03 medical and health sciences, Multiple Sclerosis, Relapsing-Remitting, 0302 clinical medicine, Adjuvants, Immunologic, Humans, Prospective Studies, REBIFLECT, Interferon beta-1a/therapeutic use [MeSH], Adjuvants, Immunologic [MeSH], Injector, Humans [MeSH], Prospective Studies [MeSH], Multiple Sclerosis/drug therapy [MeSH], Substance-Related Disorders [MeSH], Reflection, Interferon beta-1a sc, Adherence, Injections, Subcutaneous [MeSH], Multiple Sclerosis, Relapsing-Remitting/drug therapy [MeSH], Feedback [MeSH], Rebif, Original Research, Rebismart, Interferon beta-1a

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/35428903
https://repository.publisso.de/resource/frl:6485545

Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn’s disease and ulcerative colitis included in randomised controlled trials

Autoren: Peyrin-Biroulet, Laurent Arkkila, Perttu Armuzzi, Alessandro et al.

Weitere Verfasser: Peyrin-Biroulet, Laurent Arkkila, Perttu Armuzzi, Alessandro et al.

Quelle: BMC Gastroenterol
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Dipòsit Digital de la UB
instname
BMC Gastroenterology, Vol 24, Iss 1, Pp 1-12 (2024)

Schlagwörter: B72HH48FLU (Infliximab), RC799-869, Inflammatory bowel disease, Desenvolupament de medicaments, Crohn Disease, Human health sciences, Randomized Controlled Trials as Topic, Remission Induction, Biobetter, Induction Chemotherapy, Diseases of the digestive system. Gastroenterology, Tumour necrosis factor-alpha inhibitors, INDUCTION THERAPY, General medicine, internal medicine and other clinical medicine, Malalties inflamatòries intestinals, 3. Good health, Treatment Outcome, CT-P13 SC, Life Sciences & Biomedicine, 9RV78Q2002 (vedolizumab), Adult, MAINTENANCE THERAPY, PHASE-3, Tumour necrosis factor-α inhibitors, Injections, Subcutaneous, Gastrointestinal Agents/therapeutic use/adverse effects/administration & dosage, Subcutaneous infliximab, Infliximab/therapeutic use/administration & dosage/adverse effects, Drug development, Inflammatory bowel diseases, Antibodies, Monoclonal, Humanized, Sciences de la santé humaine, Vedolizumab, 1117 Public Health and Health Services, Induction Chemotherapy/methods, Gastrointestinal Agents, Humans, Science & Technology, Gastroenterology & Hepatology, Bioinnovative, Research, 3202 Clinical sciences, 1103 Clinical Sciences, Gastroentérologie & hépatologie, Infliximab, Antibodies, Monoclonal, Humanized/therapeutic use/adverse effects/administration & dosage, Antibodies, Monoclonal, Humanized/administration, Induction Chemotherapy/methods [MeSH], Gastrointestinal Agents/adverse effects [MeSH], Randomized Controlled Trials as Topic [MeSH], Colitis, Ulcerative/drug therapy [MeSH], Infliximab/therapeutic use [MeSH], Gastrointestinal Agents/therapeutic use [MeSH], Infliximab/adverse effects [MeSH], Remission Induction [MeSH], Gastrointestinal Agents/administration, Crohn Disease/drug therapy [MeSH], Adult [MeSH], Humans [MeSH], Treatment Outcome [MeSH], Infliximab/administration, Injections, Subcutaneous [MeSH], Antibodies, Monoclonal, Humanized/therapeutic use [MeSH], Antibodies, Monoclonal, Humanized/adverse effects [MeSH], Crohn Disease/drug therapy, Colitis, Ulcerative, Colitis, Ulcerative/drug therapy, Gastroenterology & hepatology

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38539103
https://hdl.handle.net/2445/214164
https://doaj.org/article/5d1ccaccfa3b4ae6bc5630baead360c9
https://hdl.handle.net/2268/327981
https://doi.org/10.1186/s12876-024-03163-5
http://hdl.handle.net/10138/574634
https://repository.publisso.de/resource/frl:6499351

Cardiovascular Effects of Combining Subcutaneous or Intravenous Esketamine and the MAO Inhibitor Tranylcypromine for the Treatment of Depression: A Retrospective Cohort Study

Autoren: Philipp Ritter Vera M Ludwig Michael Bauer et al.

Quelle: CNS Drugs

Schlagwörter: Adult, Male, Neurology, Antidepressive Agents/adverse effects [MeSH], Aged [MeSH], Ketamine/pharmacology [MeSH], Tranylcypromine/pharmacology [MeSH], Depressive Disorder, Major/drug therapy [MeSH], Psychopharmacology, Cohort Studies [MeSH], Ketamine/administration, Male [MeSH], Heart Rate/drug effects [MeSH], Drug Interactions [MeSH], Original Research Article, Monoamine Oxidase Inhibitors/administration, Tranylcypromine/administration, Pharmacotherapy, Tranylcypromine/adverse effects [MeSH], Dose-Response Relationship, Drug [MeSH], Antidepressive Agents/administration, Female [MeSH], Adult [MeSH], Humans [MeSH], Blood Pressure/drug effects [MeSH], Monoamine Oxidase Inhibitors/pharmacology [MeSH], Retrospective Studies [MeSH], Middle Aged [MeSH], Depressive Disorder, Treatment-Resistant/drug therapy [MeSH], Administration, Intravenous [MeSH], Injections, Subcutaneous [MeSH], Monoamine Oxidase Inhibitors/adverse effects [MeSH], Psychiatry, Young Adult [MeSH], Ketamine/adverse effects [MeSH], Neurosciences, Antidepressive Agents/pharmacology [MeSH], Monoamine Oxidase Inhibitors, Injections, Subcutaneous, Blood Pressure, Cohort Studies, Depressive Disorder, Treatment-Resistant, 03 medical and health sciences, 0302 clinical medicine, Heart Rate, Humans, Drug Interactions, Aged, Retrospective Studies, Depressive Disorder, Major, Dose-Response Relationship, Drug, Middle Aged, Antidepressive Agents, 3. Good health, Administration, Intravenous, Female, Ketamine, Tranylcypromine

Zugangs-URL: https://link.springer.com/content/pdf/10.1007/s40263-021-00837-6.pdf
https://pubmed.ncbi.nlm.nih.gov/34283390
https://www.ncbi.nlm.nih.gov/pubmed/34283390
https://link.springer.com/content/pdf/10.1007/s40263-021-00837-6.pdf
https://pubmed.ncbi.nlm.nih.gov/34283390/
https://link.springer.com/article/10.1007/s40263-021-00837-6
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8354966
https://repository.publisso.de/resource/frl:6464961

Renal effects of the serine protease inhibitor aprotinin in healthy conscious mice

Autoren: Stefan Wörner Bernhard N. Bohnert Matthias Wörn et al.

Quelle: Acta Pharmacol Sin
Acta Pharmacol. Sin. 43, 111-120 (2022)

Schlagwörter: Male, 0301 basic medicine, 0303 health sciences, Serine Proteinase Inhibitors, Dose-Response Relationship, Drug, Molecular Structure, Injections, Subcutaneous, Serine Endopeptidases, Mice, Transgenic, Article, 3. Good health, Aprotinin, Epithelial Sodium Channel, Renal Dysfunction, Serine Proteases, Sodium, Mice, Structure-Activity Relationship, 03 medical and health sciences, Kidney Tubules, Dose-Response Relationship, Drug [MeSH], Female [MeSH], Molecular Structure [MeSH], sodium, Structure-Activity Relationship [MeSH], Serine Endopeptidases/metabolism [MeSH], Animals [MeSH], Aprotinin/metabolism [MeSH], renal dysfunction, Aprotinin/administration, serine proteases, Injections, Subcutaneous [MeSH], Mice, Transgenic [MeSH], Mice [MeSH], Serine Proteinase Inhibitors/adverse effects [MeSH], Kidney Tubules/pathology [MeSH], Male [MeSH], Serine Proteinase Inhibitors/metabolism [MeSH], aprotinin, epithelial sodium channel, Aprotinin/adverse effects [MeSH], Kidney Tubules/metabolism [MeSH], Serine Proteinase Inhibitors/administration, Animals, Female, ddc:610

Dateibeschreibung: application/pdf

Zugangs-URL: https://www.nature.com/articles/s41401-021-00628-1.pdf
https://pubmed.ncbi.nlm.nih.gov/33758357
https://www.nature.com/articles/s41401-021-00628-1
https://www.ncbi.nlm.nih.gov/pubmed/33758357
https://www.nature.com/articles/s41401-021-00628-1.pdf
https://pubmed.ncbi.nlm.nih.gov/33758357/
https://opus4.kobv.de/opus4-fau/frontdoor/index/index/docId/22451
https://push-zb.helmholtz-muenchen.de/frontdoor.php?source_opus=61696
https://repository.publisso.de/resource/frl:6442926

Effect of Maternal Electroacupuncture on Perinatal Nicotine Exposure-Induced Lung Phenotype in Offspring

Autoren: Ji, Bo Zhao, Guo-Zhen Sakurai, Reiko et al.

Quelle: Lung. 194(4)

Schlagwörter: 32 Biomedical and Clinical Sciences (for-2020), 3201 Cardiovascular Medicine and Haematology (for-2020), Pediatric (rcdc), Tobacco (rcdc), Behavioral and Social Science (rcdc), Perinatal Period - Conditions Originating in Perinatal Period (rcdc), Tobacco Smoke and Health (rcdc), Lung (rcdc), Neurosciences (rcdc), Complementary and Integrative Health (rcdc), Reproductive health and childbirth (hrcs-hc), 3 Good Health and Well Being (sdg), Animals (mesh), Electroacupuncture (mesh), Female (mesh), Hypothalamo-Hypophyseal System (mesh), Injections, Subcutaneous (mesh), Lung (mesh), Nicotine (mesh), Nicotinic Agonists (mesh), PPAR gamma (mesh), Phenotype (mesh), Pituitary-Adrenal System (mesh), Pregnancy (mesh), Prenatal Exposure Delayed Effects (mesh), Rats (mesh), Rats, Sprague-Dawley (mesh), Wnt Signaling Pathway (mesh), beta-Endorphin (mesh), Nicotine, Smoking, Electroacupuncture, Lung development, PPAR gamma, Wnt signaling, Lung (mesh), Pituitary-Adrenal System (mesh), Hypothalamo-Hypophyseal System (mesh), Animals (mesh), Rats (mesh), Rats, Sprague-Dawley (mesh), Prenatal Exposure Delayed Effects (mesh), Nicotine (mesh), beta-Endorphin (mesh), PPAR gamma (mesh), Nicotinic Agonists (mesh), Electroacupuncture (mesh), Injections, Subcutaneous (mesh), Pregnancy (mesh), Phenotype (mesh), Female (mesh), Wnt Signaling Pathway (mesh), Electroacupuncture, Lung development, Nicotine, PPARγ, Smoking, Wnt signaling, Animals (mesh), Electroacupuncture (mesh), Female (mesh), Hypothalamo-Hypophyseal System (mesh), Injections, Subcutaneous (mesh), Lung (mesh), Nicotine (mesh), Nicotinic Agonists (mesh), PPAR gamma (mesh), Phenotype (mesh), Pituitary-Adrenal System (mesh), Pregnancy (mesh), Prenatal Exposure Delayed Effects (mesh), Rats (mesh), Rats, Sprague-Dawley (mesh), Wnt Signaling Pathway (mesh), beta-Endorphin (mesh), 1102 Cardiorespiratory Medicine and Haematology (for), Respiratory System (science-metrix), 3201 Cardiovascular medicine and haematology (for-2020)

Zugangs-URL: https://escholarship.org/uc/item/05j66659

Tratamento da flacidez músculo aponeurótica acentuada da parede abdominal, experiência de 26 anos

Autoren: CALDEIRA, ALBERTO MAGNO LOTT SOLÓRZANO, JOHN FORTUNATO JAULIS MAURICIO, KELLY STELLE CARRIÓN

Quelle: Revista Brasileira de Cirurgia Plástica, Volume: 34, Issue: 4, Pages: 378-383, Published: 16 JUN 2023

Schlagwörter: Abdominoplastia, Tela subcutânea, Secondary treatment, Abdominoplasty, Muscular atrophy, Tratamento secundário, Muscular diastasis, Subcutaneous mesh, Atrofia muscular, Diástase muscular

Dateibeschreibung: text/html

Zugangs-URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1983-51752019000300378&lng=en&tlng=en

Urothelial toxicity of esketamine in the treatment of depression

Autoren: Findeis, Hannelore Sauer, Cathrin Cleare, Anthony et al.

Quelle: Psychopharmacology (Berl)

Schlagwörter: Adult, Male, Depressive Disorder, Dose-Response Relationship, Drug, Injections, Subcutaneous, Middle Aged, Antidepressive Agents, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, Injections, Intravenous, Antidepressive Agents/adverse effects [MeSH], Depressive Disorder/drug therapy [MeSH], Urothelium/metabolism [MeSH], Original Investigation, Depression, Ketamine/administration, Male [MeSH], Depressive Disorder/urine [MeSH], Esketamine, Ketamine/urine [MeSH], Dose-Response Relationship, Drug [MeSH], Urothelium/drug effects [MeSH], Antidepressive Agents/administration, Female [MeSH], Depressive Disorder/diagnosis [MeSH], Adult [MeSH], Humans [MeSH], Antidepressive Agents/urine [MeSH], Middle Aged [MeSH], Affective disorder, Injections, Subcutaneous [MeSH], Urothelial toxicity, Injections, Intravenous [MeSH], Ketamine/adverse effects [MeSH], Side effects, Humans, Female, Ketamine, Urothelium

Zugangs-URL: https://link.springer.com/content/pdf/10.1007/s00213-020-05611-y.pdf
https://pubmed.ncbi.nlm.nih.gov/32712681
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7561544
https://pubmed.ncbi.nlm.nih.gov/32712681/
https://kclpure.kcl.ac.uk/portal/en/publications/urothelial-toxicity-of-esketamine-in-the-treatment-of-depression(9dd473da-f9b2-4cda-9b40-d2cbf8f0d528).html
https://link.springer.com/article/10.1007/s00213-020-05611-y
https://link.springer.com/content/pdf/10.1007/s00213-020-05611-y.pdf
https://repository.publisso.de/resource/frl:6466890